These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 34176192)

  • 1. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
    Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
    Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 4. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
    Furlanetto J; Marmé F; Loibl S
    Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
    Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of sacituzumab govitecan in solid tumors.
    Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
    J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
    N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
    Baek G; Jung L; Duong A; Gralow J
    J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
    Kang C
    Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
    Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
    Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
    Zangardi ML; Spring LM; Nagayama A; Bardia A
    Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.